David Balli
Bayer (United States)(US)Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research, Lung Cancer Treatments and Mutations, FOXO transcription factor regulation
Most-Cited Works
- → Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy(2018)732 cited
- → EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration(2018)732 cited
- → Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction(2020)515 cited
- → Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA(2016)326 cited
- → First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743(2022)254 cited
- → Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer(2016)245 cited
- → Foxm1 transcription factor is required for lung fibrosis and epithelial‐to‐mesenchymal transition(2013)177 cited
- → Association between pathologic response and survival after neoadjuvant therapy in lung cancer(2023)150 cited
- → Foxm1 transcription factor is required for macrophage migration during lung inflammation and tumor formation(2011)99 cited
- → MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma(2021)97 cited